3SBio receives updated proposal for merger and going private

In China, 3SBio, a company focused on researching, developing, manufacturing and marketing biopharmaceutical products, reported they have received an updated merger proposal. The letter is from Dr. Jing Lou , 3SBIO Chairman and CEO, CPEChina Fund, and CITIC Private Equity Funds Management. In the new proposal letter, Dr. Lou and CITIC PE proposed to increase the merger consideration payable to holders of ordinary shares, par value $0.0001 per share, of 3SBio and holders of American Depository Shares of the company, $2.20 per Share, or $15.40 per ADS, under the merger agreement to $2.3857 per Share, or $16.70 per ADS, pursuant to a proposed amendment to the merger agreement.